{"id":"NCT01092507","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers","officialTitle":"A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-09","completion":"2011-10","firstPosted":"2010-03-25","resultsPosted":"2013-12-02","lastUpdate":"2013-12-25"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Encephalitis","Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"Japanese encephalitis chimeric virus vaccine (JE-CV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)","otherNames":[]}],"arms":[{"label":"JE-CV Group","type":"EXPERIMENTAL"},{"label":"SA14-14-2 vaccine Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare a single dose of Japanese encephalitis (JE) chimeric virus vaccine (JE-CV) with a single dose of SA14-14-2 live vaccine as primary vaccination in infants and toddlers.\n\nPrimary Objective:\n\n* To demonstrate the non-inferiority of the antibody response 28 days after vaccine administration of one dose of JE CV (administered on Day 0) compared to the antibody response after one dose of the SA14-14-2 control vaccine (administered on Day 0).\n\nSecondary Objectives:\n\n* To describe the immune response to JE in both vaccine groups in JE-CV virus and SA14-14-2 virus before and after a single dose of JE CV or a single dose of SA14-14-2 vaccine\n* To describe the safety profile in all vaccinated subjects up to 28 days and all serious adverse events (SAEs) up to 6 months after vaccination.\n* To describe only related SAEs and all death from 6 month to 12-month follow-up.","primaryOutcome":{"measure":"Number of Participants With Japanese Encephalitis Seroconversion After Vaccination With One Dose of Either Japanese Encephalitis Chimeric Vaccine (JE-CV) or Japanese Encephalitis Live Vaccine (SA14-14-2) (CD.JEVAX®)","timeFrame":"Day 0 through Day 28 after vaccination","effectByArm":[{"arm":"Japanese Encephalitis Chimeric Vaccine (JE-CV)","deltaMin":125,"sd":null},{"arm":"Japanese Encephalitis Live Vaccine (SA14-14-2)","deltaMin":127,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":3,"countries":["Thailand"]},"refs":{"pmids":["24717964"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":147},"commonTop":["Injection Site Tenderness","Irritability","Appetite Loss","Crying Abnormal","Drowsiness"]}}